Program-at-a-Glance

/Program-at-a-Glance
Program-at-a-Glance 2018-04-22T11:39:44+00:00

PRELIMINARY. Exact schedule times to be advised.

Tuesday, May 15, 2018

+
07:30  -  17:00

Registration Open

    +
    09:30  -  09:50
    Hall A

    Welcome by Conference Co-Chairpersons

      Ruti Alon, Founder and CEO, Medstrada
      Ora Dar, PhD, Israel Innovation Authority
      Nissim Darvish, MD, PhD, Senior Managing Director, OrbiMed

      +
      09:50  -  11:20
      Hall A

      Plenary Session

        09:50-10:35 Arie S. Belldegrun MD, FACS, Founder, Kite Pharma; Executive Chairman & Co-Founder, Allogene Therapeutics

        10:35-11:20 Francois Maisonrouge, Senior Managing Director, Evercore Partners

        +
        11:20  -  11:50

        Coffee Break

            Chair: Prof. David Sidransky, MD, Johns Hopkins School of Medicine and Israel Biotech Fund, Co-Founder and General Partner

            Immune Oncology
            11:50-11:55 Prof. David Sidransky, MD, Johns Hopkins School of Medicine and Israel Biotech Fund, Co-Founder and General Partner

            11:55-12:35 Prof. Jeffrey A. Sosman, MD, Director, Melanoma Program, Director, Faculty Development, Co-Leader, Translational Research in Solid Tumors, Robert H. Lurie Comprehensive Cancer Center of Northwestern University

            12:35-12:50 Company presentation to be advised

            12:50-13:05 Yaron Pereg, CEO, Kahr Medical: “KAHR Medical Dual Signaling Proteins (DSP) Platform – the Next Generation of Cancer Immunotherapy”

            13:05-13:20 Tehila Ben Moshe, CEO,Biond Biologics: “Developing Unique, Creative and Breakthrough Immunotherapies”

            13:20-13:35 Aviv Boim, CEO, Tikcro Technologies: “Immune Oncology – Selective Blocking Antibodies”

            13:35-13:50 Irit Carmi-Levy, Drug Development Manager, BiolineRX: “AGI-134: Small Molecule Inducing Hyper-acute, Multi-arm Immune Response Targeting Tumor-specific Neoantigens”

            13:50-15:20 Lunch Break

            Oncology
            15:20-15:40 Alan Wise, PhD, CEO, IOmet Pharma (a wholly-owned subsidiary of MSD): “MSD Immuno-Oncology Overview”

            15:40-16:00 Tal Zaks, MD, PhD, Chief Medical Officer Moderna Therapeutics: “Translating mRNA Vaccines and Therapeutics into IO Agents”

            16:00-16:15 Dror Harats, MD, CEO Vascular Therapeutics: “MOSPD2: A Novel Target for Antibody-Mediated Killing of Tumor Cells”

            16:15-16:30 Roni Mamluk, CEO, Ayala Pharmaceuticals: “Ayala – A New Clinical Stage Precision Oncology Company”

            16:30-16:45 Ori Kalid, Co-Founder & CEO, Pi Therapeutics: “Novel First-in-class Inhibitors of Protein Degradation – an Unfolding Story”

            16:45-17:00 Company presentation to be advised

            17:15-17:45 Roundtable Discussion: Precision Medicine in Oncology
            Panelists:
            Prof. Jeffrey A. Sosman, MD, Director, Melanoma program, Director, Faculty Development, Co-Leader, Translational Research in Solid Tumors, Robert H. Lurie Comprehensive Cancer Center of Northwestern University
            Alan Wise, PhD, CEO, IOmet Pharma (a wholly-owned subsidiary of MSD)
            Tal Zaks, MD, PhD, Chief Medical Officer Moderna Therapeutics
            Roni Mamluk, CEO, Ayala Pharmaceuticals
            Dror Harats, MD, CEO Vascular Therapeutic:

              Chair: Yael Weiss, MD, PhD, Vice President Business Development, Ultragenyx

              11:50-12:00 Yael Weiss, MD, PhD, Vice President Business Development, Ultragenyx: “Opening Remarks”

              12:00-12:15 Julia Hawkins, Partner, LocalGlobe: “The Journey of a Parent to a Child with a Rare Genetic Condition”

              12:15-12:35 Tal Zaks, MD, PhD, Chief Medical Officer Moderna Therapeutics: “Moderna mRNA Therapies for Rare Genetic Diseases”

              12:35-12:50 BatSheva Kerem, SpliSense: “Antisense Oligonucleotide Based Treatment for Cystic Fibrosis”

              12:50-13:05 Company presentation to be advised

              13:05-13:20 Yael Weiss, MD, PhD, Vice President Business Development, Ultragenyx: “From Small Molecules to Gene Therapy and Everything in Between”

              13:20-13:35 Nissim Benvenisty, New Stem Ltd: Human Haploid Pluripotent Stem Cells”

              13:35-13:50  Aleks Schein, ART BioScience: “mRNA Therapeutics for the Treatment of Rare Diseases”

              13:50-15:20 Lunch Break

              15:50-16:05 Natalie Yivgi Ohana, PhD, Founder & Chief Scientist, Minovia Therapeutics: “Mitochondria Augmentation Therapy for Rare Mitochondrial Diseases”

              16:05-16:20 Company presentation to be advised

              16:20-16:35 Chris Adams, PhD, MBA, Chief Executive Officer, Cydan II Inc: “Rare Disease Company Formation”

              16:35-16:50 Daniel Fischer, Founder at Tevard Biosciences: “A parent on the race to find a therapy for Dravet Syndrome”

              16:50-17:05 Tauhid Ali, PhD, Vice President and Head of TAK-celerator, Takeda: “A Rare Disease Unit within Big Pharma”

              17:05-17:30 Panel: Rare Diseases – Not a Rare Success. Developing Therapies for Rare Genetic Diseases
              Moderator: Yael Weiss, MD, PhD, Vice President Business Development, Ultragenyx
              Panelists:
              Julia Hawkins, Partner, LocalGlobe
              Tauhid Ali, PhD, Vice President and Head of TAK-celerator, Takeda
              Chris Adams, PhD, MBA, Chief Executive Officer, Cydan II Inc.
              Daniel Fischer, Founder at Tevard Biosciences

                Chair: Iris Grossman, PhD, CEO, IsraGene Ltd

                 

                11:50-12:00 Iris Grossman, PhD, CEO, IsraGene Ltd: “Introduction”

                12:00-12:20 TBA “Regulatory Landscape, from Cures Act to INFORMED, Recent Guidances and Future Perspective”

                12:20-12:35 Erhan Bilal, PhD, IBM T.J. Watson Research / Computational Biology Center: “Digital Endpoints for Clinical Trials”

                12:35-12:50 Marc Funk, COO & President, Lonza Pharma & Biotech: “Novel Tools to Accelerate Early Drug R&D”

                12:50-13:05 Daphna Laifenfeld, PhD, Head, Personalized Medicine & Diagnostics, Teva Pharmaceuticals: “Data Driven Repurposing of Existing Drugs”

                13:05-13:50 Panel Discussion
                Panelists: All

                13:50-15:20 Lunch Break

                15:20-15:35 Dan Vesely, Co-founder, CliniCrowd, Partner at Sdemagroup: “Patient-driven R&D and the Power of Social Media for Therapeutics”

                15:35-15:50 Alon Ben Noon, CEO & Co-Founder, NeuroSense: “Repurposed and Abbreviated ALS Disease Modifying Therapeutic Development”

                15:50-16:05 Company presentation to be advised

                16:05-16:20 Company presentation to be advised

                16:20-16:35 Nadav Kidron, CEO, OraMed Pharmaceuticals: “Abbreviated Drug Development: Patient-centered Approaches to Innovation”

                16:35-16:50 Company presentation to be advised

                16:50-17:05 David Harel, CytoReason: “Data-driven Approach to Discover and Develop Immunotherapy Solutions”

                17:05-17:20 Ellen Leinfuss, Certara: “Modeling and Simulations Lead Efficient and Effective Drug Development”

                17:20-17:50 Company presentation to be advised

                17:50-18:00 Iris Grossman, PhD, CEO, IsraGene Ltd: “Closing Remarks”

                Wednesday, May 16, 2018

                +
                09:30  -  09:50
                Hall A

                Plenary Session

                  Aharon Aharon, CEO, Israel Innovation Authority

                  +
                  09:50  -  10:50
                  Hall A

                  Corporate Panel

                    Moderator: David Cassak, Managing Partner, Innovation In Medtech

                    Panelists:
                    Michael Martin, PhD, Global Head, Takeda Ventures, Inc.
                    Zeev Zehavi, Vice President of Venture Investments, Johnson & Johnson Innovation – JJDC, Inc. (JJDC)
                    Gil Bar-Nahum, PhD, Managing Director, Jefferies International, London, UK
                    Michal Silverberg, Managing Director, Novartis Venture Fund
                    Chris Kaster, Vice President, Business Development, Venture Capital Investing, Boston Scientific
                    Simon Gisby, Managing Director, Deloitte Corporate Finance LLC
                    David Neustaedter, Vice President, Venture Capital Medtronic
                    William Shen, Executive Director, Business Development, Bristol-Myers Squibb

                    +
                    10:50  -  11:30
                    Hall A

                    Plenary Session

                      Bruce R. Rosengard, MD, Chief Medical Science and Technology Officer, Johnson & Johnson Medical Devices Companies

                      +
                      11:30  -  12:00

                      Coffee Break

                          Chair: Prof. Simon Benita, PhD, Head of Nano Delivery Systems, Hebrew University of Jerusalem

                          Session 1: Nanomedicine: Future Promises

                          12:00-12:30 Anand Subramony, PhD, Vice President, Novel Product Technologies, MedImmune: “Nanomedicine and its Role in New Medical Therapeutics”

                          12:30-13:00 Prof. Dina Ben-Yehuda, PhD, Dean, Hadassah-Hebrew University Faculty of Medicine “Targeted Nanoparticles for Improved Hematological Cancers”

                          Session 2: Presentation of Start-ups

                          13:00-13:15 Alon Moran, CEO, BioNanoSim Ltd: “Innovative Nano-carriers for Improved Delivery and Drug Performance”

                          13-15-13:30 Company presentation to be advised

                          13:30-13:45 Yoram Ashery, CEO, Nobio Ltd: “Nobio Nanoparticles for Permanent Antimicrobial Protection”

                          13:45-14:00 Company presentation to be advised

                          14:00-15:30 Lunch Break

                          15:30-15:45 Amir Bahar, PhD, CEO, Nurami Ltd: “Scaffolds of Electrospun Nanofibers for Soft Tissue Repair”

                          15:45-16:00 Shlomzion Shen, PhD, MBA, CEO, Seevix Material Sciences Ltd: “Seevix Spidersilk “SVXgro”: First Man-Made Spidersilk Produced With Bio- and Nano-Technology”

                          Session 3: Nanotechnology Up-scaling Challenges: From Bench to the Market

                          16:00-16:07 Company presentation to be advised

                          16:07-16:15 Company presentation to be advised

                          16:15-16:30 Company presentation to be advised

                          16:30-16:45 Prof. Simon Benita, PhD, Head of Nano Delivery Systems, Hebrew University of Jerusalem: “Challenges in the Development and Up-scaling of Drug-loaded Nanoparticles”

                          Session 4 Closing Lecture

                          16:45-17:15 Prof. Ronit Satchi-Fainaro, PhD, Head, Cancer Angiogenesis & Nanomedicine Laboratory, Sackler Faculty of Medicine, Tel Aviv University: “Reverting Cancer’s Poor Prognosis using Precision Nanomedicines Based on Molecular Fingerprints of Long-term vs Short-term Survivors“

                           

                           

                           

                           

                            Chair: Gil Granot-Mayer, CEO, Yeda R&D – Technology Transfer, Weizmann Institute of Science

                            Block 1 – Life Cycle of Technology Transfer – From Initial Disclosure to Success Story

                            12:00 Gil Granot-Mayer, CEO, YEDA; “Introduction”

                            12:00-12:35 Panel:  Looking at Both Sides of the Curtain with Technology Transfer – New Technology Transfer Practices, the Convergence of Digital Technology into the Pharma World, Commercializing Platforms, and Better Understanding of what is Driving TTO Policy
                            Moderator: Mr. Benjamin Soffer, CEO, T3
                            Panelists:
                            Tamar Raz, CEO. Hadasit
                            Sylvie Luria, CEO Sheba
                            Yaron Daniely, CEO, Yissum
                            Shlomo Nimrodi, CEO, Ramot
                            Netta Cohen, CEO, BGN Technologies
                            Gil Granot-Mayer, CEO, Yeda
                            Larry Loev, CEO, Ariel Scientific Innovations

                            12:35-13:00 Showcase of New Start-ups from Academia Part 1 of 3
                            Moderator: Larry Loev, CEO, Ariel Scientific Innovations
                            Yitshak Francis, Scientific Advisor, Qrons; Ariel University
                            Yoram Eshel, CEO, On-Sight; Weizmann Institute of Science
                            Prof. Fuad Fares, Founder, CanCuRX; Haifa University
                            Jessica Weiss, CEO, Lydus Medical; Clalit

                            13:00-13:55 Major Israeli Success Stories in Life Sciences – Fireside Chat with Professors who Championed Academic Innovation into Industry
                            Moderator: Shay Sela, VP, Business Development of Life Sciences, YEDA
                            Prof. Michel Revel, MD, PhD, Professor Emeritus, Weizmann Institute of Science and Chief Scientist, Kadimastem Ltd
                            Prof. Yechezkel “Chezy” Barenholz, Hebrew University of Jerusalem and Founder of Numerous Startups
                            Prof. Moussa B.H. Youdim, Prof. Emeritus at the Technion, Founder of Numerous Startups, and President & Chief Scientific Officer at Youdim Pharmaceuticals
                            Prof. Avigidor Scherz, Weizmann Institute of Science and Developed the technology behind Steba BioTech

                            14:00-15:30 Lunch Break

                            Block 2 – Creating the Environment for Successful Technology Transfer:

                            15:30-16:10 Funding and Performing Translational Research – Models in Taking Bench Side Research to Market. (Collaboration with the IIA; Horizon 2020; NIH; Spark (Stanford) programs)
                            Moderator: Gil Granot-Mayer, CEO, YEDA
                            Michael Salgaller, Supervisor, Invention Development and Marketing Unit (IDMU), Technology Transfer Center, National Cancer Institute, National Institutes of Health
                            Pasi Sorvisto, Director, SPARK Finland Program
                            Esther Hagai, CEO, FutuRx
                            Prof. Eli Hazum, Head, IDEA program at YEDA
                            Aviv Zeevi Balasiano, VP, Head of Division – Technology Infrastructure Israel Innovation Authority
                            Eyal Zimlichman, Deputy Director General, Chief Medical Officer and Chief Innovation Officer at Sheba Medical Center

                            16:10-16:30 Showcase of New Start-ups from Academia Part 2 of 3
                            Moderator: Larry Loev, CEO, Ariel Scientific Innovations
                            Nadav Peles, Co-Founder, Acting CEO, Ta Geza; Sheba
                            Prof. Noam Shomron, CSO, Variantyx; TAU
                            Tomer Behor, CEO, RenewSenses; Hebrew University

                            16:30-17:15 View of the Israeli Life Science Ecosystem – How do we Realize the Potential?
                            Moderator: Daphna Murvitz, Co-founder & CEO, 8400 Health Network
                            Zeev Zehavi, Vice President, Venture Investments JnJ
                            Prof. David Sidransky, MD, General Partner at the Israel Biotech Fund
                            Einat Zisman, Former CEO of FutuRx
                            Yuval Ofek, Founder & Chairman at DayTwo
                            Roni Mamluk, CEO at Ayala Pharmaceuticals
                            Itai Kela, Senior Director, Head of Healthcare and Biotechnology, Israel Innovation Authority

                            17:15-17:50 Showcase of New Start-ups from Academia Part 3 of 3
                            Moderator: Larry Love, CEO, Ariel Scientific Innovations
                            Daria Lemann-Blumenthal, CEO, Belkin Laser; Sheba
                            Hila Goldman Aslan, CEO, DiA Imaging Analysis; Ben Gurion University
                            Prof. Ayala Pollack, MD, Inventor & Medical Director, OphtimedRx; Clalit
                            Seth Salpeter, Co-Founder & CTO, CuResponse, Weizmann Institute of Science

                            17:40 Gil Granot-Mayer, CEO, YEDA; “Closing Remarks”

                              Metabolic Chairs: Irit Yaniv, MD, General Partner, Accelmed & Prof. Moshe Phillip, Director of the Institute for Endocrinology and Diabetes, Israel National Center for Childhood Diabetes

                              Ophthalmology Chair: Barak Azmon, MD, Managing Director, Notal Vision

                              Metabolic Session (Presentations + Q&A by co-chairs)

                              12:00-12:17 Company presentation to be advised

                              12:17-12:34 Company presentation to be advised

                              12:34-12:51 Eran Atlas, Co-founder & CEO, DreaMed Diabetes

                              12:51-13:08 Boaz Brill, CEO, GluSense: “GluSense GlydeTM CGM – a long-term implantable glucose sensor”

                              13:08-13:25 Company presentation to be advised

                              13:25-13:42 Company presentation to be advised

                              13:42-13:59 Company presentation to be advised

                              14:00-15:30 Lunch Break

                              Ophthalmology Session

                              15:30-15:45 Ram Ben-Yehuda, Senior VP Operations, Orcam Technologies: “OrCam – Sophisticated Technology for the Low Vision and Blind”

                              15:45-16:00 Aryeh Batt, Co-Founder & CEO, Precise Bio: “Bio-manufacturing“

                              16:00-16:15 Nahum Ferera, CEO & Co-Founder, EyeYon Medical

                              16:15-16:30 Yaakov Milstain, CEO, Nano-Retina: “Artificial Retina”

                              16:30-16:45 Ron Schneider, Medical Device Director, BeyeOnics-Elbit “Placing the Surgeon in the Center – A Novel 3D Visualization Platform for Eye Surgery Providing Transparent Display, Data Overlay and Guidance”

                              16:45-17:30 Ophthalmic Panel:
                              Panelists:
                              Prof. Anat Loewenstein MD, MHA, Head, Ophthalmology Division, Tel Aviv Medical Center
                              Prof. Ehud Assia, MD, Head, Ophthalmology Division, Meir Medical Center
                              Barak Azmon, MD, Managing Director, Notal Vision

                              Thursday, May 17, 2018

                              +
                              09:10  -  09:25
                              Hall A

                              Winner of Startup Competition

                                Dr. Ami Appelbaum, Chairman IIA

                                +
                                09:25  -  11:25
                                Hall A

                                Plenary Session

                                  09:25-10:05 Philip Nelson, Director of Engineering at Google Research

                                  10:05-10:45 Paul R. Biondi, Senior Vice President, Head of Business Development, Bristol-Myers Squibb

                                  10:450-11:25 Troy Cox, Chief Executive Officer, Foundation Medicine

                                  +
                                  11:25  -  11:50

                                  Coffee Break

                                      Co-Chairs: Anat Naschitz, Managing Director, Orbimed Advisors and Allen Kamer, Managing Partner, OurCrowd Qure

                                      John D. Halamka, MD, MS, Chief Information Officer, Beth Israel Deaconess System: “Emerging Innovations in Healthcare Information Technology”

                                      Joshua Milner, MD, Chief, Laboratory of Allergic Diseases, National Institute of Health: “Building a System and a Culture of Sharing in the Ever Blurring Line of Clinical and Research Genomics”

                                      Elie Lobel, CEO, Orange Healthcare: “Leveraging Technology & Data For Consumer’s Health Improvement”

                                      AI AND CYBER
                                      Ziv Ofek, Founder and CEO, MDClone
                                      Amir Magner, CEO, CyberMDX

                                      PATIENT DRIVEN CARE
                                      Ofer Tzadik, COO, TytoCare
                                      Ariel Beery, CEO, MobileODT
                                      Ran Shaul, Co-Founder and Chief Product Officer, K Health

                                      DATA AND BIOLOGY – A 2 WAY STREET
                                      Prof. Shai Shen-Orr, Chief Scientist, CytoReason; Faculty of Medicine, Technion
                                      Prof. Zohar Yakhini, DNA storage

                                        Chair: Varda Shalev, MD, Managing Director, Morris Kahn & Maccabi Research and Innovation Institute at Maccabi Health Care Services

                                        Miro Venturi, PhD, Global Head – Diagnostics Biomarkers & Personalized Healthcare, F. Hoffmann-La Roche Ltd

                                        David Fenstermacher, PhD, VP R&D-Bioinformatics, Medimmune

                                        Prof. Gideon Rechavi, MD, PhD, Head, Sheba Cancer Research Center

                                        Shai Rosenberg, MD, Neuro-Oncology & Head of Cancer Computational Biology Lab., Hadassah-Hebrew University Medical center

                                        Randy J. Prebula, Partner, Hogan Lovells, Washington, D.C.

                                        Varda Shalev, MD, Managing Director, Morris Kahn & Maccabi Research & Innovation Institute at Maccabi Health Care Services

                                          Chair: Tetsuyuki Maruyama, PhD, Chief Scientific Officer, Dementia Discovery Fund, SV Life Sciences Managers

                                          Tetsuyuki Maruyama, PhD, Chief Scientific Officer, Dementia Discovery Fund, SV Life Sciences Managers: “Where are we in Research, Treatment and Prevention of AD and Dementia “

                                          Prof. Nir Giladi, MD, Director, Neurology Division, Tel Aviv Sourasky Medical Center

                                          Panel: “Innovations in-development” to Improve treatment for Brain diseases – challenge the traditional drug development frameworks.
                                          Panelists:

                                          Panel: Getting closer to validated Biomarkers
                                          Panelists:
                                          Hartmuth Kolb, PhD, Head of Neuroscience Biomarkers, Janssen Research & Development
                                          Prof. John Gallacher, Director, Dementia Platform UK, University of Oxford